Tumor stem cells of malignant gliomas
DOI:
https://doi.org/10.25305/unj.89634Keywords:
neural stem cells, tumor stem cells, gliomas, glioblastomas, CD133 cellsAbstract
Data of last researches, devoted to tumor stem sells, that are identified in malignant gliomas, are given. Tumor stem cells are similar to ordinary neural stem cells of the brain. They express CD133+ molecule marker, are able to migrate and infiltrate intact brain tissue. They cause relapses and recurrent growth of malignant tumors. Tumor stem cells are resistant to chemical and radiotherapy and lead to growth tumor at experimental animals with ummunodeficit.
Tumor stem cells — are a new subject for investigation and development of new treatment strategies for brain gliomas.
References
Глиомы головного мозга / Ю.А. Зозуля, И.Г. Васильева, А.Я. Главацкий [и др.]. — К.: УИПК ЕксОб, 2007. — 630 с.
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme / M.J. McGirt, K.D. Than, J.D. Weingart [et al.] // J. Neurosurg. — 2009. —V.110, N3. —P.583–588.
A novel five–transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning / S. Miraglia, W. Godfrey, A.H. Yin [et al.] // Blood. — 1997. — V.90. — P.5013–5021.
Xie Z. Molecular and cell biology of brain tumor stem cells: lessons from neural progenitor/stem cells / Z. Xie, L.S. Chin // Neurosurg. Focus. — 2008. — V.24, N3–4. — P.123–129.
Holland E.C. Glioblastoma multiforme: the terminator / E.C. Holland //Proc. Natl. Acad. Sci. USA. — 2000. — V.97, N12. — P.6242–6244.
Vascular endothelial growth factor A contributes to glioma–induced migration of human marrow stromal cells (hMSC) / C. Schichor, T. Birnbaum, N. Etminan [et al.] // Exp. Neurol. — 2006. — V.199, N2. — P.301–310.
Identification of human brain tumour initiating cells / S.K. Singh, C. Hawkins, I.D. Clarke [et al.] // Nature. — 2004. — V.432, N7. — P.396–401.
Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study / E. Shaw, R. Arusell, B. Scheithauer [et al.] // J. Clin. Oncol. — 2002. — V.20, N9. — P.2267–2276.
Dandy W. Removal of right cerebral hemispheres for certain tumors with hemiplegia: preliminary report / W. Dandy // J.A.M.A. — 1928. — V.90. — P.823–825.
Malignant glioma: who benefits from adjuvant chemotherapy? / L.M. DeAngelis, P.C. Burger, S.B. Green, J.G. Cairncross // Ann. Neurol. — 1998. — V.44, N4. — P.691–695.
A randomized trial on dose–response in radiation therapy of low–grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844 / A.B. Karim, B. Maat, R. Hatlevoll et al. // Int. J. Radiat. Oncol. Biol. Phys. — 1996. — V.36, N3. — P.549–556.
Лисяный Н.И. Изменение иммунных реакций при различных видах глиом / Н.И. Лисяный // Глиомы головного мозга / под ред. Ю.А. Зозули. — К.: УИПК ЕксОб, 2007. — C.235–252.
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune detects in patients with malignant glioma / P. Fecci, D. Mitchell, J. Whitesides [et al.] // Cancer Res. — 2006. — V.66, N6. — P.3294–3302.
Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas / K.S. Aboody, A. Brown, N.G. Rainov [et al.] // Proc. Natl. Acad. Sci. USA. — 2000. — V.97, N23. — P.12846–12851.
Bidlingmaier S. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells / S. Bidlingmaier, Z. Xiaodong, L. Bin // J. Mol. Med. — 2008. — V.86, N9. — P.1025–1032.
Dietrich J. Mechanisms of disease: the role of stem cells in the biology and treatment of gliomas / J. Dietrich, J. Imitola, S. Kesari // Nat. Clin. Pract. Oncol. — 2008. — V.5, N7. — P.393–404.
Isolation and characterization of tumorigenic, stem–like neural precursors from human glioblastoma / R. Galli, E. Binda, U. Orfanelli [et al.] // Cancer Res. — 2004. — V.64. — P.7011–7021.
Tu S.M. Stem–cell origin of metastasis and heterogeneity in solid tumours / S.M. Tu, S.H. Lin, C.J. Logothetis // Lancet Oncol. — 2002. — V.3, N8. — P.508–513.
Selective migration of neuralized embryonic stem cells to stem cell factor and media conditioned by glioma cell lines / P. Serfozo, M.S. Schlarman, C. Pierret [et al.] // Cancer Cell Int. — 2006. — V.6. — P.234–268.
AC133, a novel marker for human hematopoietic stem and progenitor cells / A.H. Yin, S. Miraglia, E.D. Zanjani [et al.] // Blood. — 1997. — V.90. — P.5002–5012.
Neural stem cells as novel cancer therapeutic vehicles / S. Yip, R. Sabetrasekh, R.L. Sidman, E.Y. Snyder // Eur. J. Cancer. — 2006. — V.42, N9. — P.1298–1308.
Isolation of cancer stem cells from adult glioblastoma multiforme / X. Yuan, J. Curtin, Y. Xiong [et al.] // Oncogene. — 2004. — V.23. — P.9392–9400.
Constitutive EGFR signaling confers a motile phenotype to neural stem cells / J.A. Boockvar, D. Kapitonov, G. Kapoor [et al.] // Mol. Cell. Neurosci. — 2003. — V.24, N4. — P.1116–1130.
Kosztowski T. Applications of neural and mesenchymal stem cells in the treatment of Gliomas / T. Kosztowski, H. Zaidi, A. Quiñones–Hinojosa // Expert Rev. Anticancer Ther. — 2009. — V.9, N5. — P.597–612.
Stem cells, cancer, and cancer stem cells / T. Reya, S.J. Morrison, M.F. Clarke [et al.] // Nature. — 2001. — V.414. — P.105–111.
Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects / P. Vaupel // J. Natl. Cancer Inst. — 2001. — V.93, N93. — P.266–276.
Targeting cancer stem cells through L1CAM suppresses glioma growth / S. Bao, Q. Wu, Z. Li [et al.] // Cancer Res. — 2008. — V.68, N15. — P.6043–6048.
Direct isolation of human central nervous system stem cells / N. Uchida, D.W. Buck, D. He [et al.] // Proc. Natl. Acad Sci. USA. — 2000. — V.97. — P.14720–14725.
Bonnet D. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell / D. Bonnet, J.E. Dick // Nat. Med. — 1997. — V.3 — P.730–737.
Gillespie GY.CD133 is a marker of bioenergetic stress in human glioma / C.E. Griguer, C.R. Oliva, E. Gobin [et al.] // PLoS One. — 2008. — V.3, N11. — P.3655.–3665.
Identification and expansion of human colon–cancer–initiating cells / L. Ricci-Vitiani, D.G. Lombardi, E. Pilozzi [et al.] // Nature. — 2007. — V.445. — P. 111–115.
Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4 / Z. Liang, T. Wu, H. Lou [et al.] // Cancer Res. — 2004. — V.64, N12. — P.4302–4308.
Nestin and CD133: valuable stem cell–specific markers for determining clinical outcome of glioma patients / M. Zhang, T. Song., L. Yang [et al.] // J. Exp. Clin. Cancer Res. — 2008. — V. 24, N27. — P.85.
The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane prot rusions / D. Corbeil, K. Roper, A. Hellwig [et al.] // J. Biol. Chem. — 2000. — V.275. — P.5512–5520.
Cuo W. Cancer stem cells / W. Guo, J.L. Lasky, H. Wu // Pediatr. Res. — 2006. — V.59. — P.59–64.
Mizrak D. CD133: molecule of the moment / D. Mizrak, M. Brittan, M. Alison // J. Pathol. — 2008. — V.214. — P.3–9.
MMP-2, MT1-MMP and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines / C. Ries, V. Egea, M. Karow [et al.] // Blood. — 2007. — V.109, N9. — P.4055–4063.
Stiles C.D. Glioma stem cells: a midterm exam / C.D. Stiles, D.H. Rowitch // Neuron. — 2008. — V.58, N6. — P.832–846.
Xu F. Stem cells tropism for malignant gliomas / F. Xu, J.H. Zhu // Neurosci. Bull. — 2007. — V.23, N6. — P.363–369.
CXCR4 is a major chemokine receptor on glioma cells and mediates their survival / Y. Zhou, P.H. Larsen, C. Hao, V.W. Yong // J. Biol. Chem. — 2002. — V.277, N51. — P.49481–49487.
Identification and expansion of the tumorigenic lung cancer stem cell population / A. Eramo, F. Lotti, G. Sette [et al.] // Cell. Death Differ. — 2008. — V.15. — P.504–514.
Low-dose radiation.enhances surviving-mediated virotherapy against malignant glioma stem cells / S. Nandi, I.V. Ulasov, M.A. Tyler [et al.] // Cancer Res. — 2008. — V.68, N14. — P.5778–5784.
Sun L. Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury / L. Sun, J. Lee, H.F. Fine // J. Clin. Invest. — 2004. — V.113, N9. — P.1364–1374.
Characterization of CD133+hepatocellular carcinoma cells as cancer stem/progenitor cells / A. Suetsugu, M. Nagaki, H. Aoki [et al.] // Biochem. Biophys. Res. Commun. — 2006. — V.351. — P.820–824.
Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model / K. Hakamura, Y. Ito, Y. Kawano [et al.] // Gene Ther. — 2004. — V.11, N14. — P.1155–1164.
Neural stem cell migration toward gliomas in vitro / O. Heese, A. Disko, D. Zirkel [et al.] // Neurooncol. — 2005. — V.7. N4. — P.476–484.
Effects of hypoxia on the proliferation and differentiation of NSCs / L.L. Zhu, L.Y. Wu, D.T. Yew, M. Fan // Mol. Neurobiol. — 2005. — V.31. — P.231–242.
Incorporation of CXCR4 into membrane lipid rafts primes homing–related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient / M. Wysoczynski, R. Reca, J. Ratajczak [et al.] // Blood. — 2005. V.105, N1. — P.40–48.
Neural stem cell targeting of glioma is dependent on phosphoinositide-3-kinase signalling / S.E. Kendall, J. Najbauer, H.F. Johnston [et al.] // Stem Cells. — 2008. — V.26, N6. — P.1575–1586.
Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines / T. Birnbaum, J. Roider, C.J. Schankin [et al.] // J. Neurooncol. — 2007. — V.83, N3. — P.241–247.
Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor / N.O. Schmidt, W. Przylecki, W. Yang [et al.] // Neoplasia. — 2005. — V.7, N6. — P.623–629.
Hadjipanayis C.G. Tumor initiating cells in malignant gliomas: biology and implications for c–Myc is required for maintenance of glioma cancer stem cells / C.G. Hadjipanayis, E.G. Van Meir // J. Mol. Med. — 2009. — V.87, N4. — P.363–374.
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors / J.B. Rubin, A.L. Kung, R.S. Klein [et al.] // Proc. Natl. Acad. Sci. USA. — 2003. — V.100, N23. — P.13513–13518.
Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4 / M. Ehtesham, X. Yuan, P. Kabos [et al.] // Neoplasia. — 2004. — V.6, N3. — P.287–293.
Sakariassen P.O. Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies / P.O. Sakariassen, H. Immervoll, M. Chekenya // Neoplasia. — 2007. — V.9. — P.882–892.
Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas / M.J. McGirt, K.L. Chaichana, F.J. Attenello [et al.] // Neurosurgery. — 2008. — V.63, N4. — P.700–707.
Beier D. Temozolomide preferentially depletes cancer stem cells in glioblastoma / D. Beier, S. Rhrl, D.R. Pillai [et al.] // Cancer Res. — 2008. — V.68, N14. — P.5706–5715.
Wen P.Y. Malignant gliomas in adults / P.Y. Wen, S. Kesari // New Engl. J. Med. — 2008. — V.359, N5. — P.492–507.
Cancerous stem cells can arise from pediatric brain tumors / H.D. Hemmati, I. Nakano, J.A. Lazareff [et al.] // Proc. Natl. Acad. Sci. USA. — 2003. — V.100, N25. — P.15178–15183.
Tumor environment dictates medulloblastoma cancer stem cell expression and invasive phenotype / B. Annabi, S. Rojas-Sutterlin, C. Laflamme [et al.] // Mol Cancer Res. — 2008. — V.6, N6. — P.907–916.
Blazek E.R. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia / E.R. Blazek, J.L. Foutch, G. Maki / /Int J. Radiat. Oncol. Biol. Phys. — 2007. — V.67. — P.1–5.
Rafii S. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration / S. Rafii, D. Lyden // Nat. Med. — 2003. — V.9, N6. — P.702–712.
Pardal R. pplying the principles of stem–cell biology to cancer / R. Pardal, M. Clarke, S. Morrison // Nat. Rev. Cancer. — 2003. — V.3. — P.895–902.
Cytomegalovirus infection and interferon–gamma modulate major histocompatibility complex class I expression on neural stem cells / M.C. Cheeran, Z. Jiang, S. Hu S [et al.] // J. Neurovirol. — 2008. — V.14, N5. — P.437–447.
CD133(+) and CD133(–) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles / D. Beier, P. Hau, M. Proescholdt [et al.] // Cancer Res. — 2007. — V.67, N6. — P.4010–4015.
Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas / M. Kyeung, K. Shi Yean, J. Xun [et al.] // Lab. Invest. — 2008. — V.88. — P. 808–815.
Biological and genetic characteristics of tumor–initiating cells in colon cancer / K. Ieta, F. Tanaka, N. Haraguchi [et al.] // Cancer Ann. Surg. Oncol. — 2008. — V.15. — P.638–648.
Glioma stem cells: a midterm exam / M.S. Lesniak, H. Brem, C.D. Targ Stiles, D.H. Rowitch // Neuron. — 2008. — V.58, N6. — P.832–846.
Expression of VEGFR–2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors / M. Peichev, A.J. Naiyer, D. Pereira [et al.] // Blood. — 2000. — V.95. — P.952–958.
Relationship of glioblastoma multiforme to the lateral ventricles predicts survival following tumor resection / K.L. Chaichana, M.J. McGirt, J. Frazier [et al.] // J. Neurooncol. — 2008. — V.89, N2. — P.219–224.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2010 A. N. Lisyany, N. I. Lisyany
This work is licensed under a Creative Commons Attribution 4.0 International License.
Ukrainian Neurosurgical Journal abides by the CREATIVE COMMONS copyright rights and permissions for open access journals.
Authors, who are published in this Journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the Journal under the terms of Creative Commons Attribution License, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this Journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form of which it has been published by the Journal (for example, to upload the work to the online storage of the Journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this Journal is included.
